Journal Summary - Discover more summaries and articles from M3 India

Journal Summaries

Oncology

Lung/Thoracic Oncology

Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer

JAMA | Jan 26, 2019 Lung/Thoracic Oncology

Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: An Australian population-based study

Cancer | Jan 25, 2019 Lung/Thoracic Oncology

The incidence and distribution of mediastinal lymph node metastasis and its impact on survival in patients with non-small-cell lung cancers 3 cm or less: Data from 2292 cases

European Journal of Cardio-Thoracic Surgery | Jan 25, 2019 Lung/Thoracic Oncology

Incidence, patterns and prognosis of first distant recurrence after surgically treated early stage endometrial cancer: Results from the multicentre FRANCOGYN study group

European Journal of Surgical Oncology | Jan 24, 2019 Lung/Thoracic Oncology

Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study

Journal of Clinical Oncology | Jan 22, 2019 Lung/Thoracic Oncology

PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data

Lung Cancer | Jan 22, 2019 Lung/Thoracic Oncology

Characterization of squamous cell lung cancers from Appalachian Kentucky

Cancer Epidemiology, Biomarkers & Prevention | Jan 22, 2019 Lung/Thoracic Oncology

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial

The Lancet Oncology | Jan 21, 2019 Lung/Thoracic Oncology

Necitumumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

Lung Cancer | Jan 21, 2019 Lung/Thoracic Oncology

Survival of patients with head and neck cancer with metachronous multiple primary tumors is surprisingly favorable

Head & Neck | Jan 21, 2019 Lung/Thoracic Oncology

« Prev 1 … 103 104 105 106 107 … 149 Next »

Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer

Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: An Australian population-based study

The incidence and distribution of mediastinal lymph node metastasis and its impact on survival in patients with non-small-cell lung cancers 3 cm or less: Data from 2292 cases

Incidence, patterns and prognosis of first distant recurrence after surgically treated early stage endometrial cancer: Results from the multicentre FRANCOGYN study group

Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study

PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data

Characterization of squamous cell lung cancers from Appalachian Kentucky

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial

Necitumumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

Survival of patients with head and neck cancer with metachronous multiple primary tumors is surprisingly favorable

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

Gut Health Disorders and its Management

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

MIP: Traumatic Brain Injury : Dr Nikhilesh Jain

Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer

Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: An Australian population-based study

The incidence and distribution of mediastinal lymph node metastasis and its impact on survival in patients with non-small-cell lung cancers 3 cm or less: Data from 2292 cases

Incidence, patterns and prognosis of first distant recurrence after surgically treated early stage endometrial cancer: Results from the multicentre FRANCOGYN study group

Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study

PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data

Characterization of squamous cell lung cancers from Appalachian Kentucky

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial

Necitumumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

Survival of patients with head and neck cancer with metachronous multiple primary tumors is surprisingly favorable

BRI or BMI: What is More Efficient?

Enhancing Conventional Diabetes Management with Lifestyle and Nutritional Interventions

Gut Health Disorders and its Management

Addressing Sleep Disorders with Integrative Solutions: From Pharmaceuticals to Natural Remedies

MIP: Traumatic Brain Injury : Dr Nikhilesh Jain

Select Specialty

Select Topic